Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Case Reports
Share your love
Ocumension Submits NDA for Zerviate in China
Nicox SA announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a new drug application (NDA) seeking approval for commercialization of Zerviate (cetirizine ophthalmic solution), 0.24%, in China. The intended use of Zerviate is for the treatment of ocular…
Tepezza Improves Proptosis in Patients With Chronic TED
Horizon Therapeutics has announced positive and statistically significant topline results from its randomized, double-masked, placebo-controlled Phase 4 clinical trial evaluating TEPEZZA for the treatment of adults with chronic thyroid eye disease (TED) and low CAS, a measure of disease activity.…
Ultomiris Poised for EU Approval as NMOSD Treatment
AstraZeneca’s Ultomiris (ravulizumab) has received a recommendation for marketing authorization in the European Union (EU) for the treatment of adult patients who are anti-aquaporin-4 (AQP4) antibody positive (Ab+) and have neuromyelitis optica spectrum disorder (NMOSD). If authorized, Ultomiris would become…
Positive Results for Dry AMD Treatment by LumiThera
LumiThera announced the 24-month data from its LIGHTSITE III multicenter clinical trial. The results showed sustained vision improvement in subjects with dry age-related macular degeneration (AMD) who were treated with the Valeda Light Delivery System. LumiThera conducted LIGHTSITE III, a…
Selagine and Grifols Team Up for DED Eye Drops
Selagine announced a global collaboration with Grifols to develop and commercialize immunoglobulin eye drops for dry eye disease. Financial terms of the agreement were not disclosed. As per the agreement, Selagine will receive an upfront payment and annual collaboration fee,…
Frontera’s Trial for Retinitis Pigmentosa Kicks Off
Frontera Therapeutics has initiated a clinical trial for its gene therapy, FT-002, which is intended for the treatment of X-linked retinitis pigmentosa (XLRP). The first patient has already been given a dose of the gene therapy product. FT-002 is Frontera’s…